Meeting
2020 ASCO Quality Care Symposium
Use of antiemetic prophylaxis and oral breakthrough medication for highly emetogenic chemotherapy (HEC) in a large community oncology network.
Authors
Garrett Young
OneOncology, Nashville, TN
Garrett Young, Stephen Matthew Schleicher, Edward Arrowsmith, Stacey McCullough, Sylvia S. Richey, Johnetta Blakely, Natalie R. Dickson, Lee S. Schwartzberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
On-Demand Poster Session: Quality, Safety, and Implementation Science
Track
Quality, Safety, and Implementation Science
Sub Track
Toxicity Prevention, Assessment, and Management
Citation
J Clin Oncol 38, 2020 (suppl 29; abstr 253)
DOI
10.1200/JCO.2020.38.29_suppl.253
Abstract #
253
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting.
First Author: P. J. Hesketh
Poster
2023 ASCO Annual Meeting
Guideline-concordant use of olanzapine as part of a 4-drug antiemetic regimen for high emetic risk chemotherapy across the state of Michigan.
First Author: Ashley Bowen
Poster
2022 ASCO Quality Care Symposium
Patterns of olanzapine prescribing for those receiving highly emetogenic chemotherapy.
First Author: Daniel S Childs
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari